Vise Technologies Inc. Purchases 13,916 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Vise Technologies opened a position in Edwards Lifesciences, buying 13,916 shares worth approximately $1.2 million in the third quarter. Institutional investors collectively own 79.46% of the company’s stock.
• Edwards reported quarterly earnings of $0.80 per share, above the $0.74 consensus estimate, and revenue of $1.72 billion, up 10.5% year over year and ahead of expectations.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $108.88. The article also notes that rising competition in TAVR could pressure future market share and growth.

Vise Technologies Inc. purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 13,916 shares of the medical research company's stock, valued at approximately $1,201,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. MGO One Seven LLC lifted its stake in shares of Edwards Lifesciences by 6.1% in the 3rd quarter. MGO One Seven LLC now owns 37,772 shares of the medical research company's stock worth $3,260,000 after purchasing an additional 2,161 shares during the period. State of Wyoming bought a new stake in Edwards Lifesciences during the third quarter valued at approximately $131,000. Peak Financial Advisors LLC increased its holdings in Edwards Lifesciences by 6.6% during the third quarter. Peak Financial Advisors LLC now owns 42,772 shares of the medical research company's stock valued at $3,692,000 after buying an additional 2,641 shares during the last quarter. Soltis Investment Advisors LLC increased its holdings in Edwards Lifesciences by 2.4% during the third quarter. Soltis Investment Advisors LLC now owns 6,479 shares of the medical research company's stock valued at $559,000 after buying an additional 153 shares during the last quarter. Finally, United Asset Strategies Inc. increased its holdings in Edwards Lifesciences by 1.6% during the third quarter. United Asset Strategies Inc. now owns 195,672 shares of the medical research company's stock valued at $16,890,000 after buying an additional 3,090 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on EW shares. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Thursday. Sanford C. Bernstein upped their price objective on Edwards Lifesciences from $99.00 to $106.00 and gave the stock a "market perform" rating in a research note on Thursday. Truist Financial set a $113.00 target price on Edwards Lifesciences and gave the stock a "buy" rating in a report on Wednesday. Wells Fargo & Company reiterated an "overweight" rating and set a $113.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Thursday, October 15th. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $108.88.

Edwards Lifesciences Trading Up 1.1%

Edwards Lifesciences stock opened at $101.91 on Friday. The firm has a 50 day moving average of $88.92 and a 200 day moving average of $85.78. The firm has a market capitalization of $58.68 billion, a price-to-earnings ratio of 57.58, a P/E/G ratio of 2.67 and a beta of 0.85. Edwards Lifesciences Corporation has a 12-month low of $74.66 and a 12-month high of $104.17. The company has a current ratio of 4.60, a quick ratio of 3.77 and a debt-to-equity ratio of 0.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3.02 earnings per share for the current year.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
• Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
• Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
• Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition

Insider Activity

In related news, VP Annette Brüls sold 2,644 shares of the company's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company's stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total transaction of $53,017.35. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,428,912.10. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,045 shares of company stock worth $451,596 in the last three months. Company insiders own 0.31% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.

The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.